3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
12
Breast Neoplasms
7
Neoplasm Metastasis
5
Lymphoma
5
Multiple Myeloma
4
Leukemia
4
Hematologic Neoplasms
4
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Depression
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Motor Activity
2
Malignant Female Reproductive System Neoplasm
2
Glioblastoma
2
Fatigue
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Caregiver Burden
2
Anxiety Disorders
2
Advanced Malignant Solid Neoplasm
2
Thyroid Neoplasms
1
Stroke
1
Stress Disorders, Post-Traumatic
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Initiation and Maintenance Disorders
1
Signs and Symptoms
1
Interventions
Cyclophosphamide
51
fludarabine
37
Dexamethasone
35
venetoclax
30
pembrolizumab
25
Rituximab
20
pomalidomide
18
Lenalidomide
17
Gemcitabine
17
fludarabine phosphate
15
Etoposide
14
Cytarabine
13
daratumumab
12
carfilzomib
11
Temozolomide
11
Injections
10
Calcium Dobesilate
10
glofitamab
9
Nivolumab
9
Cisplatin
9
Bortezomib
9
Azacitidine
9
selinexor
8
Vincristine
8
Immunotherapy, Adoptive
8
obinutuzumab
7
cemiplimab
7
Drug Therapy
7
Carboplatin
7
zanubrutinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Palliative Care
×
1 year
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled